New pill may shrink lung tumors before surgery in Gene-Mutated cancers
NCT ID NCT07156604
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests the drug Vebreltinib, taken as a pill for 8 weeks before surgery, in 30 people with stage IIA-IIIB non-small cell lung cancer that has a specific gene change (MET exon 14 skipping). The goal is to see if the drug can shrink tumors enough to improve surgery results. Participants will be followed for up to 3 years after surgery to monitor recurrence and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vebreltinib (a targeted cancer pill)
What this could lead to
If successful, this could show that taking Vebreltinib before surgery helps shrink lung tumors with a specific gene change, potentially improving surgical outcomes.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply widely. The drug may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center, Shanghai,
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••